2.12
+0.0098(+0.46%)
Currency In USD
Address
1 Broadway
Cambridge, MA 02142
United States of America
Phone
857 254 4445
Website
Sector
Healthcare
Industry
Biotechnology
Employees
66
First IPO Date
January 07, 2022
| Name | Title | Pay | Year Born |
| Dr. Ivana Magovcevic-Liebisch J.D., Ph.D. | President, Chief Executive Officer & Director | 903,863 | 1967 |
| Dr. David Gray Ph.D. | Chief Scientific Officer | 601,566 | 1975 |
| Ms. Jennifer Ziolkowski CPA | Chief Financial Officer | 629,080 | 1975 |
| Ms. Leah Gibson | Vice President of Investor Relations and Corporate Communications | 0 | N/A |
| Mr. Evan A. Thackaberry DABT, Ph.D. | Senior Vice President & Head of Early Development | 0 | 1973 |
| Eric Brophy | Senior Manager of Information Technology | 0 | N/A |
| Weeteck Yeo Ph.D. | Senior Vice President of Strategic Operations | 0 | N/A |
| Christian Mirescu Ph.D. | Senior Vice President & Head of Neuroimmunology | 0 | N/A |
| Ms. Sharon Morani | Senior Director of Facilities & Operations | 0 | N/A |
| Ms. April Effort M.B.A., M.S. | Vice President & Head of Corporate Development | 0 | N/A |
Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.